JP6557234B2 - 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 - Google Patents

弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 Download PDF

Info

Publication number
JP6557234B2
JP6557234B2 JP2016537333A JP2016537333A JP6557234B2 JP 6557234 B2 JP6557234 B2 JP 6557234B2 JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016537333 A JP2016537333 A JP 2016537333A JP 6557234 B2 JP6557234 B2 JP 6557234B2
Authority
JP
Japan
Prior art keywords
virus
cells
ndv
newcastle disease
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016537333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533749A (ja
JP2016533749A5 (OSRAM
Inventor
チェン，シン
キャロル，ダニエル
マッコート，マチュー
ガリンスキー，マーク
ジン，ホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2016533749A publication Critical patent/JP2016533749A/ja
Publication of JP2016533749A5 publication Critical patent/JP2016533749A5/ja
Application granted granted Critical
Publication of JP6557234B2 publication Critical patent/JP6557234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016537333A 2013-09-03 2014-09-02 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 Expired - Fee Related JP6557234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03
US61/873,039 2013-09-03
PCT/EP2014/068619 WO2015032755A1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019129161A Division JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Publications (3)

Publication Number Publication Date
JP2016533749A JP2016533749A (ja) 2016-11-04
JP2016533749A5 JP2016533749A5 (OSRAM) 2017-10-12
JP6557234B2 true JP6557234B2 (ja) 2019-08-07

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537333A Expired - Fee Related JP6557234B2 (ja) 2013-09-03 2014-09-02 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法
JP2019129161A Expired - Fee Related JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019129161A Expired - Fee Related JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Country Status (25)

Country Link
US (2) US10519426B2 (OSRAM)
EP (3) EP4101457A1 (OSRAM)
JP (2) JP6557234B2 (OSRAM)
KR (2) KR102310692B1 (OSRAM)
CN (2) CN111944767A (OSRAM)
AU (2) AU2014317215C1 (OSRAM)
CA (1) CA2922071C (OSRAM)
CY (2) CY1121993T1 (OSRAM)
DK (2) DK3508209T3 (OSRAM)
EA (2) EA202191926A3 (OSRAM)
ES (2) ES2914577T3 (OSRAM)
HK (1) HK1231393A1 (OSRAM)
HR (2) HRP20190250T1 (OSRAM)
HU (1) HUE042382T2 (OSRAM)
LT (2) LT3508209T (OSRAM)
ME (1) ME03345B (OSRAM)
MX (2) MX367768B (OSRAM)
PL (2) PL3508209T3 (OSRAM)
PT (2) PT3041490T (OSRAM)
RS (2) RS58332B1 (OSRAM)
SI (2) SI3041490T1 (OSRAM)
SM (2) SMT201900094T1 (OSRAM)
TR (1) TR201902073T4 (OSRAM)
TW (1) TWI653334B (OSRAM)
WO (1) WO2015032755A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019193662A (ja) * 2013-09-03 2019-11-07 メディミューン リミテッド 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP3288595B1 (en) * 2015-04-28 2020-12-30 The University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
EP3246410A1 (en) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
EP4121453A2 (en) * 2020-03-20 2023-01-25 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
US20220396809A1 (en) * 2021-06-03 2022-12-15 University Of Guelph Engineered newcastle disease virus vector and uses thereof
KR20250144435A (ko) * 2023-02-06 2025-10-10 사이안백 엘엘씨 변형된 piv5 백신 벡터: 제조 및 사용 방법
KR20250083186A (ko) * 2023-11-29 2025-06-09 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
WO2010091262A1 (en) * 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
KR102222157B1 (ko) * 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
KR102310692B1 (ko) * 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019193662A (ja) * 2013-09-03 2019-11-07 メディミューン リミテッド 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Also Published As

Publication number Publication date
AU2014317215C1 (en) 2019-09-12
DK3041490T3 (en) 2019-03-04
LT3041490T (lt) 2019-02-25
PL3041490T3 (pl) 2019-05-31
MX2019010364A (es) 2019-10-07
HK1225643B (en) 2017-09-15
CA2922071A1 (en) 2015-03-12
EP3041490B1 (en) 2018-11-14
EA201690425A1 (ru) 2016-08-31
AU2019204419B2 (en) 2021-09-02
EA039404B1 (ru) 2022-01-24
HRP20220653T1 (hr) 2022-06-24
US20200181581A1 (en) 2020-06-11
MX367768B (es) 2019-09-05
HRP20190250T1 (hr) 2019-05-31
US10519426B2 (en) 2019-12-31
EA202191926A2 (ru) 2021-10-29
CY1121993T1 (el) 2020-10-14
CA2922071C (en) 2022-05-03
RS58332B1 (sr) 2019-03-29
AU2014317215B2 (en) 2019-03-28
KR102285894B1 (ko) 2021-08-04
RS63291B1 (sr) 2022-06-30
HUE042382T2 (hu) 2019-06-28
CY1126790T1 (el) 2024-12-13
SMT202200214T1 (it) 2022-07-21
DK3508209T3 (da) 2022-05-30
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
KR20210048605A (ko) 2021-05-03
TW201606079A (zh) 2016-02-16
JP2016533749A (ja) 2016-11-04
AU2019204419A1 (en) 2019-07-11
LT3508209T (lt) 2022-06-10
SI3508209T1 (sl) 2023-01-31
KR20160047570A (ko) 2016-05-02
SMT201900094T1 (it) 2019-02-28
EP3508209B1 (en) 2022-03-09
EA202191926A3 (ru) 2022-01-31
TR201902073T4 (tr) 2019-03-21
ES2914577T3 (es) 2022-06-14
ME03345B (me) 2019-10-20
EP3508209A1 (en) 2019-07-10
CN111944767A (zh) 2020-11-17
US11471499B2 (en) 2022-10-18
PL3508209T3 (pl) 2022-06-13
KR102310692B1 (ko) 2021-10-12
ES2708755T3 (es) 2019-04-11
WO2015032755A1 (en) 2015-03-12
HK1231393A1 (zh) 2017-12-22
JP6862500B2 (ja) 2021-04-21
EP4101457A1 (en) 2022-12-14
JP2019193662A (ja) 2019-11-07
CN106163532B (zh) 2019-12-31
AU2014317215A1 (en) 2016-04-14
EP3041490A1 (en) 2016-07-13
US20160208222A1 (en) 2016-07-21
MX2016002771A (es) 2016-09-06
PT3508209T (pt) 2022-05-27
CN106163532A (zh) 2016-11-23
AU2014317215A8 (en) 2016-04-21
TWI653334B (zh) 2019-03-11

Similar Documents

Publication Publication Date Title
JP6862500B2 (ja) 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法
US20210169956A1 (en) Increased activity of oncolytic newcastle disease virus
CN112739359A (zh) Apmv及其用于治疗癌症的用途
US20240199705A1 (en) Chimeric newcastle disease virus expressing apmv hn and f proteins
US20230147975A1 (en) Pharmaceutical formulation comprising a combination of recombinant newcastle disease viruses for the treatment of cancer
US20220339222A1 (en) New oncolytic newcastle disease viruses and recombinant ndv strains
HK40011356B (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
HK40042398A (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
HK40011356A (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
HK1225643A1 (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
EP3868876A1 (en) New oncolytic newcastle disease viruses and recombinant ndv strains
Neault Arming, pseudotyping, and enhancing the efficacy of oncolytic measles virus for a better cancer therapeutic

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190711

R150 Certificate of patent or registration of utility model

Ref document number: 6557234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees